Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3238/arztebl.2015.0423 http://scihub22266oqcxt.onion/10.3238/arztebl.2015.0423 C4558874!4558874!26179016     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Dtsch+Arztebl+Int 2015 ; 112 (25): 423-32 Nephropedia Template TP {{tp|p=26179016|t=2015. The Diagnosis and Treatment of Systemic Lupus Erythematosus |pdf=|usr=}}{{26179016}} gab.com Text The Diagnosis and Treatment of Systemic Lupus Erythematosus JO: Dtsch Arztebl Int http://www.kidney.de/pget.php?&tw=1&pmid=26179016 #FOAvip Background: Systemic lupus erythematosus (SLE) is an autoimmune disease with a prevalence of 36.7/100 000 in Germany and a female/male ratio of 4:1. The clinical course is variable, with a broad spectrum of organ manifestations; lupus nephritis develops in about half of all patients. Methods: This review is based on a selective search of PubMed and the Cochrane Library, including current guidelines and expert recommendations. Results: Assessment of clinical symptoms, laboratory findings, and optional biopsy results are the basis for early diagnosis of SLE. All patients should be treated with antimalarials as soon as the diagnosis is confirmed. In particular, hydroxychloroquine is associated with a higher rate of remission, fewer relapses, and reduced damage in the course of the disease, even in lupus nephritis. High-dose glucocorticoids should be given only when acutely indicated; immunosuppressives such as azathioprine, methotrexate, or mycophenolate mofetil may be administered to reduce glucocorticoids, according to the EULAR recommendations. Belimumab was recently approved as add-on therapy in autoantibody-positive SLE patients with high disease activity unresponsive to standard treatment. Short-term induction pulse therapy with low-dose intravenous cyclophosphamide, as well as continued mycophenolate mofetil treatment are advances in lupus nephritis. Conclusion: The long-term prognosis for SLE has improved markedly in recent decades because of earlier diagnosis and optimized treatment. Further research and randomized controlled trials are needed for the development of specifically targeted therapies. Twit Text FOAVip The Diagnosis and Treatment of Systemic Lupus Erythematosus ????Dtsch Arztebl Int http://www.kidney.de/pget.php?&tw=1&pmid=26179016 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26179016 #FOAvip English Wikipedia <ref>{{Cite pmid|26179016}}</ref> The Diagnosis and Treatment of Systemic Lupus Erythematosus #MMPMID26179016 Kuhn A; Bonsmann G; Anders HJ; Herzer P; Tenbrock K; Schneider M Dtsch Arztebl Int 2015[Jun]; 112 (25): 423-32 PMID26179016show ga Background: Systemic lupus erythematosus (SLE) is an autoimmune disease with a prevalence of 36.7/100 000 in Germany and a female/male ratio of 4:1. The clinical course is variable, with a broad spectrum of organ manifestations; lupus nephritis develops in about half of all patients. Methods: This review is based on a selective search of PubMed and the Cochrane Library, including current guidelines and expert recommendations. Results: Assessment of clinical symptoms, laboratory findings, and optional biopsy results are the basis for early diagnosis of SLE. All patients should be treated with antimalarials as soon as the diagnosis is confirmed. In particular, hydroxychloroquine is associated with a higher rate of remission, fewer relapses, and reduced damage in the course of the disease, even in lupus nephritis. High-dose glucocorticoids should be given only when acutely indicated; immunosuppressives such as azathioprine, methotrexate, or mycophenolate mofetil may be administered to reduce glucocorticoids, according to the EULAR recommendations. Belimumab was recently approved as add-on therapy in autoantibody-positive SLE patients with high disease activity unresponsive to standard treatment. Short-term induction pulse therapy with low-dose intravenous cyclophosphamide, as well as continued mycophenolate mofetil treatment are advances in lupus nephritis. Conclusion: The long-term prognosis for SLE has improved markedly in recent decades because of earlier diagnosis and optimized treatment. Further research and randomized controlled trials are needed for the development of specifically targeted therapies. äThe Diagnosis and Treatment of Systemic Lupus Erythematosus (epmc).pdf DeepDyve Pubget Overpricing